• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CORDIS CORPORATION OPTEASE RETRIEVAL FILTER; FILTER, INTRAVASCULAR, CARDIOVASCULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CORDIS CORPORATION OPTEASE RETRIEVAL FILTER; FILTER, INTRAVASCULAR, CARDIOVASCULAR Back to Search Results
Model Number 466F220A
Medical Device Problem Code Unintended Movement (3026)
Health Effect - Clinical Codes Emotional Changes (1831); Pain (1994)
Date of Event 07/21/2021
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
Occupation: other, senior counsel, litigation.Please note that the exact event date is unknown and the event date is the complaint awareness date.It was reported that a patient underwent placement of an optease vena cava filter.The information provided indicated that the filter subsequently malfunctioned and caused tilt of the inferior vena cava (ivc) filter.The indication for the filter implant, procedural details and medical history of the patient have not been provided and there is currently no additional information available for review.The product was not returned for analysis and the sterile lot number has not been provided; therefore, no device analysis nor device history record review could be performed.The optease vena cava filter is indicated for use in the prevention of recurrent pulmonary embolism (pe) via percutaneous placement in the vena cava for patients in which anticoagulants are contraindicated, anticoagulant therapy for thromboembolic disease has failed, emergency treatment following massive pe where anticipated benefits of conventional therapy are reduced or for chronic, recurrent pe where anticoagulant therapy has failed, or is contraindicated.The purpose of a vena cava filter is to catch thrombus from the lower extremities as it travels along normal blood flow patterns up towards the heart.Ivc filter tilt has been associated with operator technique and vessel anatomy, specifically asymmetry and tortuosity.Without images available for review the reported event could not be confirmed or further clarified.Given the limited information available for review at this time, there is nothing to suggest that the reported events are related to the design and manufacturing process of the device; therefore, no corrective action will be taken.Should additional information become available, the file will be updated accordingly.Please note that this is the initial report for this product.
 
Event or Problem Description
As reported by the legal brief, the patient underwent placement of an optease vena cava filter.The report states that the filter subsequently malfunctioned and caused injury and damage to the patient including, but not limited to tilt of the inferior vena cava (ivc) filter.As a direct and proximate result of these malfunctions, the patient suffered life-threatening injuries and damages, and required extensive medical care and treatment.As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, pain and suffering, and other damages.
 
Additional Manufacturer Narrative
It was reported that a patient underwent placement of an optease vena cava filter.The information provided indicated that the filter subsequently malfunctioned and caused tilt of the inferior vena cava (ivc) filter.The patient reported becoming aware of the event approximately eight years and nine months post implant.The patient reported that mental and physical pain related to the tilted filter.The indication for the filter placement and procedural details were not provided.The filter was placed via the right femoral vein, according to the procedure log.Approximately eight years and nine months post implant an abdominal computed tomography (ct) scan was done to evaluate the filter.Results of the scan noted an approximate 20¿30-degree anterior tilt of the upper portion with the apex abutting the ivc wall.The filter is positioned such that the filter apex is located inferior to the renal veins, 1.6 cm inferior to the lower right renal vein.The product was not returned for analysis and the sterile lot number has not been provided; therefore, no device analysis nor device history record review could be performed.The optease vena cava filter is indicated for use in the prevention of recurrent pulmonary embolism (pe) via percutaneous placement in the vena cava for patients in which anticoagulants are contraindicated, anticoagulant therapy for thromboembolic disease has failed, emergency treatment following massive pe where anticipated benefits of conventional therapy are reduced or for chronic, recurrent pe where anticoagulant therapy has failed, or is contraindicated.The purpose of a vena cava filter is to catch thrombus from the lower extremities as it travels along normal blood flow patterns up towards the heart.Ivc filter tilt has been associated with operator technique and vessel anatomy, specifically asymmetry and tortuosity.Without images available for review the reported event could not be confirmed or further clarified.Pain and anxiety do not represent a device malfunction and may be related to underlying patient specific issues and undisclosed comorbidities.Given the limited information available for review at this time, there is nothing to suggest that the reported events are related to the design and manufacturing process of the device; therefore, no corrective action will be taken.Should additional information become available, the file will be updated accordingly.
 
Event or Problem Description
The filter was implanted via the patient's right femoral vein.Approximately eight years and nine months after the index procedure an abdominal computed tomography (ct) scan was done to evaluate the inferior vena cava (ivc) for an unspecified injury.The images revealed: an approximately 20-30 degree anterior tilt of the upper portion with the apex abutting the ivc wall.The filter is positioned such that the filter apex is located inferior to the renal veins, 1.6 cm inferior to the lower right renal vein.There appears to be a calcified right basilar granuloma and the aorta is atherosclerotic.Additional information received per the patient profile form (ppf) states that the patient experienced filter tilt.The patient became aware of the reported event approximately eight years and nine months after the index procedure.The patient reported that they also experienced mental and physical pain related to the tilted filter.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
OPTEASE RETRIEVAL FILTER
Common Device Name
FILTER, INTRAVASCULAR, CARDIOVASCULAR
Manufacturer (Section D)
CORDIS CORPORATION
14201 nw 60 avenue
miami lakes FL 33014
Manufacturer (Section G)
CORDIS CORPORATION
14201 nw 60 avenue
miami lakes FL 33014
Manufacturer Contact
karla castro
14201 nw 60 avenue
miami lakes, FL 33014
7863138372
MDR Report Key14179474
Report Number9616099-2022-05568
Device Sequence Number5025624
Product Code DTK
UDI-Device Identifier20705032009413
UDI-Public20705032009413
Combination Product (Y/N)N
Initial Reporter StateOH
Initial Reporter CountryUS
PMA/510(K) Number
K034050
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2012
Reporter Type Manufacturer
Report Source Other,Health Professional
Initial Reporter Occupation Other
Type of Report Initial,Followup
Report Date (Section B) 06/17/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Model Number466F220A
Device Catalogue Number466F220A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Type of Report(Section G)Initial
Initial Date Received by Manufacturer 03/25/2022
Supplement Date Received by Manufacturer05/26/2022
Initial Report FDA Received Date04/21/2022
Supplement Report FDA Received Date06/17/2022
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Is the Device Labeled for Single Use? (Y/N) Yes
Usage of Device Initial
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
UNKNOWN 0.035 BENTSON WIRE.; UNKNOWN 0.035 GUIDE WIRE.; UNKNOWN 5 FRENCH MICROPUNCTURE.; UNKNOWN CATHETER.; UNKNOWN SHEATH.; UNKNOWN.
Outcome Attributed to Adverse Event Life Threatening;
Patient Age50 YR
Patient SexMale
Patient Weight109 KG
Patient RaceWhite
-
-